Antibody recognizing antibody
An antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass, and a pharmaceutical composition and a labeling agent comprising a ligand which recognizes the antigen.
1 . An antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass.
2 . The antigen according to claim 1 , wherein the tumor mass is a solid tumor formed by subcutaneous transplantation of a cultured cancer cell.
3 . The antigen according to claim 1 , wherein the existing amount of the antigen of the solid tumor is increased in comparison with that of a cultured cell of the solid tumor.
4 . The antigen according to claim 1 , wherein the existing amount of the antigen of the solid tumor on the cell surface is increased in comparison with that of a cultured cell of the solid tumor.
5 . The antigen according to claim 1 , which is a cytoskeleton protein or a mutant thereof.
6 . The antigen according to claim 1 , which is myosin or a mutant thereof.
7 . The antigen according to claim 1 , which is a non-muscular myosin heavy chain type A or a mutant thereof.
8 . The antigen according to claim 1 , which is a part of a non-muscular myosin heavy chain type A or a mutant thereof.
9 . The antigen according to claim 1 , which is a sequence of a C-terminal domain of the protein sequence of a non-muscular myosin heavy chain type A or a mutant thereof.
10 . The antigen according to claim 9 , wherein the sequence of a C-terminal domain of the protein sequence is a sequence of the residue at position 600 to the residue at position 1,960 from the N-terminal of SEQ ID NO:17 in the Sequence Listing.
11 . The antigen according to claim 9 , wherein the sequence of a C-terminal domain of the protein sequence is any one of SEQ ID NOs:20, 21 and 22.
12 . A ligand which recognizes the antigen according to claim 1 .
13 . The ligand according to claim 12 , which is an antibody.
14 . The ligand according to claim 12 , which is a monoclonal antibody.
15 . The ligand according to claim 12 , wherein the monoclonal antibody is a human monoclonal antibody.
16 . The ligand according to claim 12 , which is a cancer reactive monoclonal antibody.
17 . The ligand according to claim 16 , wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.
18 . The ligand according to claim 12 , wherein a heavy chain hypervariable region comprises the amino acid sequences of SEQ ID NOs:1, 2 and 3 in the Sequence Listing, and a light chain hypervariable region comprises the amino acid sequences of SEQ ID NOs:4, 5 and 6 in the Sequence Listing.
19 . The ligand according to claim 12 , which comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 in the Sequence Listing and a light chain variable region containing the amino acid sequence of SEQ ID NO:8 in the Sequence Listing.
20 . A pharmaceutical composition, which comprises the ligand according to claim 12 and a pharmaceutically acceptable carrier.
21 . The pharmaceutical composition according to claim 20 , which is a targeting therapy agent.
22 . The pharmaceutical composition according to claim 20 , which targets at a cancer tissue or a cancer cell.
23 . The pharmaceutical composition according to claim 20 , which comprises an antitumor agent, an antitumor protein, an enzyme, a gene or an isotope for treatment.
24 . The pharmaceutical composition according to claim 20 , which is an antitumor agent.
25 . The pharmaceutical composition according to claim 20 , wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.
26 . The pharmaceutical composition according to claim 20 , which comprises liposome.
27 . A composition, which comprises the ligand according to claim 12 and a labeling agent.
28 . The composition according to claim 27 , which specifically labels a cancer tissue or a cancer cell.
29 . The composition according to claim 27 , wherein the cancer is gastric cancer, breast cancer, colon cancer or esophageal cancer.
30 . The composition according to claim 27 , wherein the labeling agent is a fluorescent, an enzyme, an isotope or an MRI contrast medium.
31 . A method for treating a cancer disease of a cancer disease patient, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to claim 20 ,
wherein the cancer disease patient expresses an antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass.
32 . A method for treating a cancer disease of a cancer disease patient, which comprises administering to the cancer disease patient an effective amount of the pharmaceutical composition according to claim 20 ,
wherein the cancer disease patient has a cell which can be labeled by a composition comprising a ligand which recognizes an antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass and a labeling agent.
33 . The ligand according to claim 12 , wherein the binding activity of the ligand which recognizes an antigen having a part which is exposed on the surface of a cell at the formation of a tumor mass to the antigen is from 0.5×10 6 units/mg to 2.0×10 6 units/mg.
34 . The ligand according to claim 12 , wherein the binding activity is from 0.7×10 6 units/mg to 1.5×10 6 units/mg, from 0.7×10 6 units/mg to 1.3×10 6 units/mg, or from 0.8×10 6 units/mg to 1.2×10 6 units/mg.
35 . The ligand according to claim 12 , wherein the binding activity is from 0.8×10 6 units/mg to 1.2×10 6 units/mg.